{"artifact":{"id":"experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc","artifact_type":"experiment","entity_ids":"[\"Nrf2\"]","title":"Nrf2 inhibitor ML385 mechanism validation experiment","quality_score":0.85,"created_by":"experiment_extractor","provenance_chain":"[]","content_hash":"83cdc0d8bd1eb82733cee16080d84ff543f5998937626cc5923ea22c08c38f0e","metadata":{"_origin":{"url":null,"type":"internal","tracked_at":"2026-04-10T22:49:03.899932"},"p_value":null,"protocol":"co-treatment with acteoside and ML385, assessment of ferroptosis markers","effect_size":null,"sample_size":null,"source_pmid":"41895086","extracted_at":"2026-04-10T15:49:03.770060","_schema_version":1,"experiment_type":"cell_biology","success_criteria":"loss of acteoside's anti-ferroptotic activity when Nrf2 is inhibited","expected_outcomes":"ML385 blocks acteoside's anti-ferroptotic effects","statistical_methods":null},"created_at":"2026-04-10T22:49:03-07:00","updated_at":"2026-04-10T22:49:03-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-10T22:49:03-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":"ok","contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"a960c360-306e-46f8-8e84-2427298c53c6","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"experiment_extractor"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"experiment-exp-82df3491-a40f-4136-a61e-e8b6017cc9a7","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"target_artifact_id":"experiment-exp-46757fd6-b353-4551-b105-757ecff66ef9","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"target_artifact_id":"notebook-5fe67c33ef68","link_type":"related","strength":0.125,"evidence":"Shared entity overlap (Jaccard=0.12)"},{"target_artifact_id":"wiki-therapeutics-nrf2-activator-therapy","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-proteins-nrf2","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-mechanisms-nrf2-keap1-pathway","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-mechanisms-nrf2-oxidative-stress","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-mechanisms-nrf2-pathway","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-entities-ferroptosis","link_type":"related","strength":0.54,"evidence":"Reverse: Title match: Ferroptosis"},{"target_artifact_id":"wiki-therapeutics-nrf2-activators-parkinsons-disease","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-genes-nrf2","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-ideas-payload-nrf2-activator-therapy","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-therapeutics-nrf2-activators-neuroprotection","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-mechanisms-nrf2-activators-parkinsons","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-investment-nrf2-therapeutics","link_type":"related","strength":0.7200000000000001,"evidence":"Reverse: Gene target: NRF2"},{"target_artifact_id":"wiki-cell-types-substantia-nigra-aceruloplasminemia","link_type":"mentions","strength":0.9,"evidence":"target_gene: Nrf2"}],"incoming_links":[{"source_artifact_id":"experiment-exp-82df3491-a40f-4136-a61e-e8b6017cc9a7","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"source_artifact_id":"experiment-exp-46757fd6-b353-4551-b105-757ecff66ef9","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"source_artifact_id":"notebook-5fe67c33ef68","link_type":"related","strength":0.6,"evidence":"Both artifacts share KG entity: 'nrf2'"},{"source_artifact_id":"wiki-therapeutics-nrf2-activator-therapy","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-proteins-nrf2","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-mechanisms-nrf2-keap1-pathway","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-mechanisms-nrf2-oxidative-stress","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-mechanisms-nrf2-pathway","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-entities-ferroptosis","link_type":"mentions","strength":0.6,"evidence":"Title match: Ferroptosis"},{"source_artifact_id":"wiki-therapeutics-nrf2-activators-parkinsons-disease","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-genes-nrf2","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-ideas-payload-nrf2-activator-therapy","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-therapeutics-nrf2-activators-neuroprotection","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-mechanisms-nrf2-activators-parkinsons","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-investment-nrf2-therapeutics","link_type":"mentions","strength":0.8,"evidence":"Gene target: NRF2"},{"source_artifact_id":"wiki-mechanisms-ferroptosis","link_type":"related","strength":0.55,"evidence":"Pathway match: Nrf2 signaling, ferroptosis pathway"},{"source_artifact_id":"wiki-therapeutics-nurr1-agonist-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/therapeutics-nurr1-agonist-therapy"},{"source_artifact_id":"wiki-therapeutics-tfeb-activators-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/therapeutics-tfeb-activators-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-synaptic-plasticity-therapeutics-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/therapeutics-synaptic-plasticity-therapeutics-pd"},{"source_artifact_id":"wiki-therapeutics-section-162-advanced-antioxidant-redox-therapy-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 42x in wiki/therapeutics-section-162-advanced-antioxidant-redox-therapy-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-alpha-lipoic-acid-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/therapeutics-alpha-lipoic-acid-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-personalized-treatment-plan-atypical-parkinsonism","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 6x in wiki/therapeutics-personalized-treatment-plan-atypical-parkinsonism"},{"source_artifact_id":"wiki-therapeutics-sulforaphane-nrf2-neuroprotection","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 5x in wiki/therapeutics-sulforaphane-nrf2-neuroprotection"},{"source_artifact_id":"wiki-therapeutics-multi-target-pharmacotherapy-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 8x in wiki/therapeutics-multi-target-pharmacotherapy-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-tgr5-agonist-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/therapeutics-tgr5-agonist-therapy"},{"source_artifact_id":"wiki-therapeutics-combination-therapy-cbs-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/therapeutics-combination-therapy-cbs-psp"},{"source_artifact_id":"wiki-therapeutics-cue1-device-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/therapeutics-cue1-device-pd"},{"source_artifact_id":"wiki-therapeutics-ferulic-acid-carbamate-derivatives-ad","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/therapeutics-ferulic-acid-carbamate-derivatives-ad"},{"source_artifact_id":"wiki-therapeutics-memantine","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/therapeutics-memantine"},{"source_artifact_id":"wiki-therapeutics-nrf2-activators-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 24x in wiki/therapeutics-nrf2-activators-neurodegeneration"},{"source_artifact_id":"wiki-therapeutics-pgc1-alpha-activator-therapy","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/therapeutics-pgc1-alpha-activator-therapy"},{"source_artifact_id":"wiki-therapeutics-adenosine-a2a-receptor-antagonists-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/therapeutics-adenosine-a2a-receptor-antagonists-pd"},{"source_artifact_id":"wiki-clinical-trials-ct1-dap001-ips-dopaminergic-progenitors-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-ct1-dap001-ips-dopaminergic-progenitors-pd"},{"source_artifact_id":"wiki-clinical-trials-nct05266417-nose-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-nct05266417-nose-pd"},{"source_artifact_id":"wiki-clinical-trials-apocynin-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-apocynin-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06365190-rtms-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/clinical-trials-nct06365190-rtms-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06954662-amino-acid-supplement-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-nct06954662-amino-acid-supplement-pd"},{"source_artifact_id":"wiki-clinical-trials-ab-1005-gdnf-gene-therapy-regenerate-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-ab-1005-gdnf-gene-therapy-regenerate-pd"},{"source_artifact_id":"wiki-clinical-trials-retigabine-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-retigabine-pd"},{"source_artifact_id":"wiki-clinical-trials-nct07308418-vibrotactile-stimulation-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-nct07308418-vibrotactile-stimulation-pd"},{"source_artifact_id":"wiki-clinical-trials-intranasal-insulin-glutathione-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-intranasal-insulin-glutathione-pd"},{"source_artifact_id":"wiki-clinical-trials-biib122-luma-lrrk2-inhibitor-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-biib122-luma-lrrk2-inhibitor-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06687837-autologous-dopaminergic-neurons-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-nct06687837-autologous-dopaminergic-neurons-pd"},{"source_artifact_id":"wiki-clinical-trials-nct06821230-dyadic-mindfulness-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-nct06821230-dyadic-mindfulness-pd"},{"source_artifact_id":"wiki-clinical-trials-valacyclovir-hsv1-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-valacyclovir-hsv1-pd"},{"source_artifact_id":"wiki-clinical-trials-mr-guided-focused-ultrasound-gcase-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-mr-guided-focused-ultrasound-gcase-pd"},{"source_artifact_id":"wiki-clinical-trials-pde4-inhibitor-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-pde4-inhibitor-pd"},{"source_artifact_id":"wiki-clinical-trials-nouvneu001-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-nouvneu001-pd"},{"source_artifact_id":"wiki-clinical-trials-vibrotactile-coordinated-reset-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-vibrotactile-coordinated-reset-pd"},{"source_artifact_id":"wiki-clinical-trials-pramipexole-early-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 7x in wiki/clinical-trials-pramipexole-early-pd"},{"source_artifact_id":"wiki-clinical-trials-dimethyl-fumarate-nrf2-ad-nct06850597","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/clinical-trials-dimethyl-fumarate-nrf2-ad-nct06850597"},{"source_artifact_id":"wiki-clinical-trials-bacillus-subtilis-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/clinical-trials-bacillus-subtilis-pd"},{"source_artifact_id":"wiki-hypotheses-stress-granule-dysfunction-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 5x in wiki/hypotheses-stress-granule-dysfunction-parkinsons"},{"source_artifact_id":"wiki-datasets-amp-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/datasets-amp-pd"},{"source_artifact_id":"wiki-ideas-novel-therapy-index","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 7x in wiki/ideas-novel-therapy-index"},{"source_artifact_id":"wiki-ideas-payload-glucocorticoid-receptor-modulation-therapy","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/ideas-payload-glucocorticoid-receptor-modulation-therapy"},{"source_artifact_id":"wiki-ideas-hsp70-inducer-therapies","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/ideas-hsp70-inducer-therapies"},{"source_artifact_id":"wiki-investment-oxidative-stress","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/investment-oxidative-stress"},{"source_artifact_id":"wiki-investment-glp1-receptor-agonists","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/investment-glp1-receptor-agonists"},{"source_artifact_id":"wiki-investment-oxidative-stress-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/investment-oxidative-stress-neurodegeneration"},{"source_artifact_id":"wiki-cell-types-globus-pallidus-internus-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/cell-types-globus-pallidus-internus-pd"},{"source_artifact_id":"wiki-cell-types-nigrostriatal-dopamine-terminals-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/cell-types-nigrostriatal-dopamine-terminals-pd"},{"source_artifact_id":"wiki-cell-types-melanocytes-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/cell-types-melanocytes-pd"},{"source_artifact_id":"wiki-cell-types-snc-dopamine-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/cell-types-snc-dopamine-pd"},{"source_artifact_id":"wiki-cell-types-dopaminergic-vta-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/cell-types-dopaminergic-vta-pd"},{"source_artifact_id":"wiki-cell-types-ferroptotic-neurons","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 20x in wiki/cell-types-ferroptotic-neurons"},{"source_artifact_id":"wiki-cell-types-astrocytes-homeostasis","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/cell-types-astrocytes-homeostasis"},{"source_artifact_id":"wiki-cell-types-dorsal-raphe-serotonergic-neurons-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/cell-types-dorsal-raphe-serotonergic-neurons-pd"},{"source_artifact_id":"wiki-cell-types-vulnerable-dopaminergic-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/cell-types-vulnerable-dopaminergic-pd"},{"source_artifact_id":"wiki-cell-types-substantia-nigra-aceruloplasminemia","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 30x in wiki/cell-types-substantia-nigra-aceruloplasminemia"},{"source_artifact_id":"wiki-mechanisms-reactive-oxygen-species","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/mechanisms-reactive-oxygen-species"},{"source_artifact_id":"wiki-mechanisms-neuroimmune-checkpoint-metal-oxidative-convergence-synthesis","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 14x in wiki/mechanisms-neuroimmune-checkpoint-metal-oxidative-convergence-synthesis"},{"source_artifact_id":"wiki-mechanisms-gdf15-gdf11-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/mechanisms-gdf15-gdf11-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-dna-damage-response-neurodegeneration","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/mechanisms-dna-damage-response-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-oxidative-stress-4r-tauopathies","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 25x in wiki/mechanisms-oxidative-stress-4r-tauopathies"},{"source_artifact_id":"wiki-mechanisms-mitochondrial-dysfunction-hub","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/mechanisms-mitochondrial-dysfunction-hub"},{"source_artifact_id":"wiki-mechanisms-hypoxia-neuroprotection-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/mechanisms-hypoxia-neuroprotection-parkinsons"},{"source_artifact_id":"wiki-mechanisms-cbs-oxidative-stress","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 23x in wiki/mechanisms-cbs-oxidative-stress"},{"source_artifact_id":"wiki-mechanisms-ferroptosis-alzheimers","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/mechanisms-ferroptosis-alzheimers"},{"source_artifact_id":"wiki-mechanisms-transcriptional-regulation","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 10x in wiki/mechanisms-transcriptional-regulation"},{"source_artifact_id":"wiki-mechanisms-circadian-rhythm-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/mechanisms-circadian-rhythm-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-ferroptosis-pathway","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/mechanisms-ferroptosis-pathway"},{"source_artifact_id":"wiki-mechanisms-mlcs-quantification-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/mechanisms-mlcs-quantification-pd"},{"source_artifact_id":"wiki-mechanisms-nrf2-signaling-neurodegeneration","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/mechanisms-nrf2-signaling-neurodegeneration"},{"source_artifact_id":"wiki-mechanisms-microglial-metabolic-reprogramming","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/mechanisms-microglial-metabolic-reprogramming"},{"source_artifact_id":"wiki-mechanisms-ubiquitin-proteasome-ad-pathway","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/mechanisms-ubiquitin-proteasome-ad-pathway"},{"source_artifact_id":"wiki-mechanisms-dna-damage-repair","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/mechanisms-dna-damage-repair"},{"source_artifact_id":"wiki-mechanisms-oxidative-stress-comparison","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/mechanisms-oxidative-stress-comparison"},{"source_artifact_id":"wiki-mechanisms-ferroptosis","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/mechanisms-ferroptosis"},{"source_artifact_id":"wiki-technologies-digital-therapeutics-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/technologies-digital-therapeutics-pd"},{"source_artifact_id":"wiki-technologies-digital-biomarkers-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/technologies-digital-biomarkers-pd"},{"source_artifact_id":"wiki-technologies-wearable-sensors-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/technologies-wearable-sensors-pd"},{"source_artifact_id":"wiki-technologies-ai-movement-analysis-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/technologies-ai-movement-analysis-pd"},{"source_artifact_id":"wiki-biomarkers-alpha-synuclein-seed-kinetics-pd","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/biomarkers-alpha-synuclein-seed-kinetics-pd"},{"source_artifact_id":"wiki-events-mds-2026-neuroprotection-neurorestorative-parkinsons","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 11x in wiki/events-mds-2026-neuroprotection-neurorestorative-parkinsons"},{"source_artifact_id":"wiki-entities-sqstm1-p62","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 15x in wiki/entities-sqstm1-p62"},{"source_artifact_id":"wiki-entities-ros","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/entities-ros"},{"source_artifact_id":"wiki-entities-ppar","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/entities-ppar"},{"source_artifact_id":"wiki-entities-tumor-necrosis-factor","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 4x in wiki/entities-tumor-necrosis-factor"},{"source_artifact_id":"wiki-experiments-alpha-synuclein-aggregation-triggers-sporadic-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/experiments-alpha-synuclein-aggregation-triggers-sporadic-pd"},{"source_artifact_id":"wiki-experiments-glp1-responder-prediction-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/experiments-glp1-responder-prediction-pd"},{"source_artifact_id":"wiki-experiments-alpha-syn-saa-kinetics-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/experiments-alpha-syn-saa-kinetics-pd"},{"source_artifact_id":"wiki-experiments-synaptic-mitochondrial-resilience-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/experiments-synaptic-mitochondrial-resilience-pd"},{"source_artifact_id":"wiki-experiments-alpha-synuclein-spreading-neurodegeneration-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/experiments-alpha-synuclein-spreading-neurodegeneration-pd"},{"source_artifact_id":"wiki-experiments-combination-therapy-sequencing-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/experiments-combination-therapy-sequencing-pd"},{"source_artifact_id":"wiki-experiments-dopaminergic-neuron-selective-vulnerability-pd","link_type":"mentions","strength":0.44999999999999996,"evidence":"Content: NRF2 mentioned 2x in wiki/experiments-dopaminergic-neuron-selective-vulnerability-pd"},{"source_artifact_id":"wiki-diseases-psp","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 26x in wiki/diseases-psp"},{"source_artifact_id":"wiki-diseases-corticobasal-syndrome","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 9x in wiki/diseases-corticobasal-syndrome"},{"source_artifact_id":"wiki-chemotherapy-resistance","link_type":"mentions","strength":0.5,"evidence":"Content: NRF2 mentioned 3x in wiki/chemotherapy-resistance"},{"source_artifact_id":"open_question-1aa28c4e-6a34-4330-bf1c-914119cb08d7","link_type":"partial_answer_for","strength":0.42,"evidence":"{\"confidence\": 0.42, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-394cc839-019b-4593-ad5b-a2c5596f76df","link_type":"bears_on_question","strength":0.45,"evidence":"{\"confidence\": 0.45, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-e8f325f7-3369-4608-b6e0-3de159a0e997","link_type":"discriminating_experiment","strength":0.82,"evidence":"{\"confidence\": 0.82, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"}],"current_artifact_id":"experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc","is_canonical":true,"supersede_chain":["experiment-exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc"]}